Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romosozumab followed by zoledronic acid versus zoledronic acid alone for prevention of bone loss after acute spinal cord injury
ACTRN12623000141640Phase 4Recruiting
- Sponsor
- Princess Alexandra Hospital
- Start
- Dec 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of romosozumab and zoledronic acid in osteoporosis (3 arms), sponsored by Princess Alexandra Hospital. Primary endpoint: Change in bone mineral density at distal femur. Started Dec 2024; status: recruiting.
02
Drugs
romosozumabzoledronic acid
03
Conditions
osteoporosis
Beyond the preview
Go deeper on ACTRN12623000141640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623000141640.